XLO Valuation

Xilio Therapeutics Inc

Add to Watchlist

Advanced Chart

0.724

+0.019(2.696%)1D

Overview
Forecast
Valuation
Earnings

XLO Relative Valuation

XLO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XLO is overvalued; if below, it's undervalued.

Historical Valuation

Xilio Therapeutics Inc (XLO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -1.36. The fair price of Xilio Therapeutics Inc (XLO) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.72 USD , Xilio Therapeutics Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：0.72

Fair

Undervalued

-1.72

Trailing

Forward

0.00

EV/EBITDA

Xilio Therapeutics Inc. (XLO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.19. The thresholds are as follows: Strongly Undervalued below -3.72, Undervalued between -3.72 and -1.96, Fairly Valued between 1.57 and -1.96, Overvalued between 1.57 and 3.34, and Strongly Overvalued above 3.34. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

1.25

EV/EBIT

Xilio Therapeutics Inc. (XLO) has a current EV/EBIT of 1.25. The 5-year average EV/EBIT is -0.29. The thresholds are as follows: Strongly Undervalued below -3.98, Undervalued between -3.98 and -2.13, Fairly Valued between 1.56 and -2.13, Overvalued between 1.56 and 3.41, and Strongly Overvalued above 3.41. The current Forward EV/EBIT of 1.25 falls within the Historic Trend Line -Fairly Valued range.

0.89

Xilio Therapeutics Inc. (XLO) has a current PS of 0.89. The 5-year average PS is 1.18. The thresholds are as follows: Strongly Undervalued below -2.49, Undervalued between -2.49 and -0.66, Fairly Valued between 3.02 and -0.66, Overvalued between 3.02 and 4.86, and Strongly Overvalued above 4.86. The current Forward PS of 0.89 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Xilio Therapeutics Inc. (XLO) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.51. The thresholds are as follows: Strongly Undervalued below -16.18, Undervalued between -16.18 and -9.35, Fairly Valued between 4.32 and -9.35, Overvalued between 4.32 and 11.16, and Strongly Overvalued above 11.16. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Xilio Therapeutics Inc. (XLO) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.66. The thresholds are as follows: Strongly Undervalued below -3.04, Undervalued between -3.04 and -1.85, Fairly Valued between 0.52 and -1.85, Overvalued between 0.52 and 1.71, and Strongly Overvalued above 1.71. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Xilio Therapeutics Inc (XLO) has a current Price-to-Book (P/B) ratio of 5.17. Compared to its 3-year average P/B ratio of 1.48 , the current P/B ratio is approximately 248.36% higher. Relative to its 5-year average P/B ratio of 1.32, the current P/B ratio is about 292.39% higher. Xilio Therapeutics Inc (XLO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -111.15%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -99.25% , the current FCF yield is about -100.00% lower.

5.17

P/B

Median3y

1.48

Median5y

1.32

-37.94

FCF Yield

Median3y

-111.15

Median5y

-99.25

Competitors Valuation Multiple

The average P/S ratio for XLO's competitors is 6.13, providing a benchmark for relative valuation. Xilio Therapeutics Inc Corp (XLO) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 242.98%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

XLO.O

Xilio Therapeutics Inc

CASI Pharmaceuticals Inc

Relmada Therapeutics Inc

Loss

47.13M

OKUR.O

Onkure Therapeutics Inc

Performance Decomposition

Market capitalization of XLO decreased by 9.65% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.36M to 8.08M.

The secondary factor is the Margin Expansion, contributed -66.83%to the performance.

Overall, the performance of XLO in the past 1 year is driven by Revenue Growth. Which is more sustainable.

242.98%

2.36M → 8.08M

Revenue Growth

-66.83%

-590.79 → -195.99

Margin Expansion

-185.80%

0.76 → -0.65

P/E Change

-9.65%